VYNE Therapeutics Inc.VYNENASDAQ
Loading
R&D Expense Growth Under PressureDecelerating
Percentile Rank10
Year-over-Year Change
Year-over-year research & development expense growth
Latest
-37.84%
↓ 178% vs avg
Percentile
P10
Near historical low
Streak
1 yr
Consecutive declineDecelerating
Average
48.77%
Historical baseline
| Period | Value |
|---|---|
| 2025 | -37.84% |
| 2024 | 89.77% |
| 2023 | -11.30% |
| 2022 | -5.93% |
| 2021 | -55.11% |
| 2020 | -19.02% |
| 2019 | 1.46% |
| 2018 | 82.68% |
| 2017 | 157.73% |
| 2016 | 285.31% |